ArticleJournal of hepatocellular carcinoma2025
CT Radiomics Combined with Metabolic-Biomarkers Enables Early Recurrence Prediction in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integration of bulk and single-cell RNA-seq data identifies a cellular senescence-related prognostic signature in liver hepatocellular carcinoma.Discover oncology · 2026Article
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of early recurrence of hepatocellular carcinoma (HCC) remains poor. This study aimed to develop and validate a radiomics model and determine potential biomarkers involved in biological pathways for early recurrence of HCC. Methods: A total of 271 HCC patients from the First Affiliated Hospital of Guilin Medical University were enrolled as the training cohort. Recurrence related radiomics features were determined by analyzing contrast-enhanced CT images, which were used for the construction of Rad-score. For external validation, we utilized both imaging and transcriptome data from 34 HCC patients in TCGA database. The identified radiomics-related genes were further validated using two independent datasets (OEP000321 and GSE14520) and immunohistochemical analysis of EEF1E1 in 38 HCC tissue samples from training cohort. Results: Rad-scores based on six radiomics features showed predictive value for early HCC recurrence in both cohorts ( Conclusion: Rad-score and radiomics gene signatures from enhanced CT effectively predicted early recurrence in HCC, while EEF1E1 might serve as an efficient biomarker for early recurrence prediction for hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.